Jordana Bieze Foster

More than a decade after the last FDA approval for a stroke drug, vampire bat saliva navigates process using updated techniques

Severe stroke patients could see greatest benefit from additional imaging information

Screening tool may be ahead of its time, as results of recent trials fail to keep up with imaging advances

Prospective single-site study sets stroke community buzzing about performance of MR imaging versus unenhanced CT for triage of stroke type and severity

A growing body of research indicates that MR diffusion-weighted imaging (DWI) can help predict risk of recurrent stroke in patients presenting with transient ischemic attack.

It's been a long, frustrating 12 years since an acute stroke drug last won over the FDA, a time in which the percentage of eligible patients actually helped by the drug has remained stuck in the single digits.

In the weeks leading up to the 2007 International Stroke Conference, stroke imaging experts could have been preparing to debate such cutting-edge topics as whether MRI or CT is best suited for the ischemic mismatch imaging techniques that one day will routinely be used to select patients for thrombolytic therapy.

It's one thing for acute stroke imaging to predict final infarct volume or a patient's risk of 90-day mortality. It's quite another for imaging to predict whether a patient will recover upper extremity dexterity or language skills, or to what extent the patient will be able to function independently.

Research from Duke University, where stress fractures of the fifth metatarsal have been the proverbial Achilles heel of more than one Blue Devil basketball star, may help team practitioners identify players at risk for this injury even before symptoms develop.